Drug manufacturer Egis saw its yr-on-yr revenue decline 5 per cent to HUF 30.4 billion (EUR 104.57 million) in the first quarter of its business year (Q4 of 2011), but after-tax profit rose 14 per cent to HUF 5.33 billion (EUR 18.33 million). The company suffered the biggest setback in western exports (down 49 per cent) and in Eastern Europe, where revenues in euro terms slipped 20 per cent.
-
Display
